Merck Serono Announces Creation of Prexton
The newly founded company will develop the mGluR programs from lead optimization up to clinical Phase I and seek partnership and licensing opportunities for further development.
Merck Serono has announced the creation of Prexton Therapeutics, the first spin-off company resulting from its Entrepreneur Partnership Program launched in April 2012.
Prexton Therapeutics will be formed around Merck Serono's R&D portfolio in the field of Parkinson's disease and will focus on programs that target the metabotropic glutamate receptors mGluR3 and mGluR4.
With a team composed of seasoned Merck Serono scientists with long-standing experience in neurology and a significant portfolio of chemical compounds stemming from Merck Serono's pre-clinical research, Prexton Therapeutics will be well positioned in the field of neurodegenerative diseases. The newly founded company will develop the mGluR programs from lead optimization up to clinical Phase I and
Related News
-
News Bringing the pharmaceutical supply chain closer to home
The pharmaceutical supply chain has encountered numerous disruptions in the last few years, impacting procurement, manufacturing, packaging, and distribution operations within the pharmaceutical industry. Read about the rise in calls for near/resh... -
News Women in Pharma: Advancing gender diversity & healthcare equality
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Humira biosimilars at discounted prices to meet market demand for accessible treatment
Several biosimilars to AbbVie’s monoclonal antibody therapeutic Humira were launched by various pharmaceutical giants this week in the US, with more expected to be released by the end of the year as the patent expires. -
News Women in Pharma: Gearing up for systemic change
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Delivering on mRNA-based therapeutics: innovations in applications and packaging
Since the onset of the COVID-19 pandemic, the innovative potential of mRNA vaccines and therapeutics has raised questions regarding their manufacturing, packaging, and storage/transportation. Learn about how the pharmaceutical supply chain is meet... -
News Novavax will provide adjuvant Matrix-M for vaccine research with 3-year partnership
Novavax, developers behind the Matrix-M adjuvant, have entered into an agreement with the Bill and Melinda Gates Medical Research Institute to provide the adjuvant in preclinical vaccine research. -
News CPHI Online Webinar Series – The CPO Perspective: Driving Healthcare Sustainability
Pharmaceutical contract packaging organisations (CPOs) offer organisations broader expertise in pharma packaging, specialist skills, and flexibility with time, efficiency, and costings for pharmaceutical companies lacking in-house packaging expert... -
News The CPO Starter Pack: Why and When to Bring in a Contract Packaging Partner
Discover the trends affecting the pharmaceutical CPO market, when and why outsourcing may be an enticing option, and what is driving pharmaceutical companies and CDMOs to partner with outsourced packaging and drug delivery organisations. ...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance